Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

(2018) Francesca Zammarchi et al.   BLOOD

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

(2016) M. J. Flynn et al.   MOLECULAR CANCER THERAPEUTICS

Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload

(2016) Arnaud C. Tiberghien et al.   ACS Medicinal Chemistry Letters

Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours

(2015) Maria Mellinas-Gomez et al.   BMC Veterinary Research

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitroand in clinical acquired resistant tumour samples

(2012) Victoria J Spanswick et al.   BMC CANCER

Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

(2011) I. Puzanov et al.   CLINICAL CANCER RESEARCH

DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057

(2011) John A. Hartley et al.   INVESTIGATIONAL NEW DRUGS

SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity

(2010) J. A. Hartley et al.   CANCER RESEARCH

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

(2009) Yelena Y. Janjigian et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

(2009) D. Hochhauser et al.   CLINICAL CANCER RESEARCH

The Pyrrolobenzodiazepine Dimer SJG-136 Forms Sequence-Dependent Intrastrand DNA Cross-Links and Monoalkylated Adducts in Addition to Interstrand Cross-Links

(2009) Khondaker M. Rahman et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY